Skip to Content
Merck
CN

SML2296

GSK180736A

≥98% (HPLC)

Synonym(s):

4-(4-Fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-5-pyrimidinecarboxamide, GSK 180736A

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H16FN5O2
CAS Number:
817194-38-0
Molecular Weight:
365.36
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD30533616
Assay:
≥98% (HPLC)
Form:
powder

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

GSK180736A, ≥98% (HPLC)

InChI

1S/C19H16FN5O2/c1-10-16(17(24-19(27)22-10)11-2-4-13(20)5-3-11)18(26)23-14-6-7-15-12(8-14)9-21-25-15/h2-9,17H,1H3,(H,21,25)(H,23,26)(H2,22,24,27)

InChI key

HEAIGWIZTYAQTC-UHFFFAOYSA-N

SMILES string

O=C(NC1=CC=C(NN=C2)C2=C1)C3=C(C)NC(NC3C4=CC=C(F)C=C4)=O

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

GSK180736A is a potent and selective dual inhibitor of a ROCK1 (Rho-associated, coiled-coil-containing protein kinase) and GRK2 (G protein-coupled receptor kinase 2). GSK180736A binds to the GRK2 active site. GSK180736A produces a significant cardiomyocytes contraction at 1 μM.
potent and selective dual inhibitor of a ROCK1 and GRK2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000118696
0000048116
0000048115
0000040344

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Clark A Sehon et al.
Journal of medicinal chemistry, 51(21), 6631-6634 (2008-10-10)
Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of this enzyme in many aspects of cardiovascular function. Here we report a series of ROCK1 inhibitors which
Renee Bouley et al.
Molecular pharmacology, 92(6), 707-717 (2017-10-27)
G protein-coupled receptor kinases (GRKs) phosphorylate activated receptors to promote arrestin binding, decoupling from heterotrimeric G proteins, and internalization. GRK2 and GRK5 are overexpressed in the failing heart and thus have become therapeutic targets. Previously, we discovered two classes of
Kristoff T Homan et al.
ACS chemical biology, 10(1), 310-319 (2014-09-23)
Selective inhibitors of individual subfamilies of G protein-coupled receptor kinases (GRKs) would serve as useful chemical probes as well as leads for therapeutic applications ranging from heart failure to Parkinson's disease. To identify such inhibitors, differential scanning fluorimetry was used

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service